Get started
Author

Claus Thielert

Observed names: C Thielert, C. Thielert, Thielert, Claus
Institution: Inflarx (Germany)
OpenAlex ID: A5091276111
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
2022 · Alexander P J Vlaar, Martin Witzenrath, et al. · The Lancet Respiratory Medicine · 152
PDF
Sinecatechins, a Defined Green Tea Extract, in the Treatment of External Anogenital Warts
2008 · Silvio Tatti, James M. Swinehart, et al. · Obstetrics and Gynecology · 151
Topical Polyphenon ® E in the treatment of external genital and perianal warts: a randomized controlled trial
2008 · E. Stockfleth, H. Beti, et al. · British Journal of Dermatology · 141
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors
2003 · C.J.A. Punt, J. Boni, et al. · Annals of Oncology · 117
A randomized, double‐blind, four‐arm parallel‐group, placebo‐controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon® E in the treatment of external genital warts
2007 · G Gross, K‐G Meyer, et al. · Journal of the European Academy of Dermatology and Venereology · 102
Heterogeneity of treatment effect of vilobelimab in COVID-19: a secondary analysis of a randomised controlled trial
2024 · Rombout B. E. van Amstel, Marleen A. Slim, et al. · Critical Care · 10
PDF
Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients
2023 · Endry H. T. Lim, Alexander P. J. Vlaar, et al. · Intensive Care Medicine Experimental · 8
PDF
Anti-C5a Vilobelimab Reduces All-cause Mortality in Critically Ill COVID-19 Patients and in Those With Severe ARDS: A Phase 3 Randomized Double-blind, Placebo-controlled Study
2023 · M. Witzenrath, A.P.J. Vlaar, et al. · 2
A phase I study of escalating doses of CCI-779 in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors
2001 · C.J.A. Punt, U. Bruntsch, et al. · European Journal of Cancer · 1
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients
2025 · Endry H T Lim, Diederik van de Beek, et al. · BMJ Open Respiratory Research
PDF
87. The safety and efficacy advantage of blocking C5a vs C5 in critically ill, COVID-19 patients: Results from PANAMO, a Phase 3 randomized controlled trial
2023 · Bruce P Burnett, Endry H T Lim, et al. · Open Forum Infectious Diseases
PDF
Vilobelimab’s effect on mortality in severe COVID-19 ARDS patients: Phase 3 RCT
2023 · Alexander Vlaar, Endry Lim, et al.
LB1529. Randomized, Controlled Phase 3 Study of anti-C5a Vilobelimab's Effect on Mortality in Critically Ill COVID-19 Patients: A Therapy for Viral Pneumonia
2022 · Bruno Mourvillier, Alexander Vlaar, et al. · Open Forum Infectious Diseases
Phase 3 RCT of C5a-Specific Vilobelimab in Severe COVID-19 Pneumonia
2022 · A P Vlaar, G Hermans, et al.
Pharmacokinetics of escalating doses of CCI-779 in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors
2001 · J. Boni, J. Korth-Bradley, et al. · European Journal of Cancer
Works count: 17
Citation count: 683
H-index: 7
I10-index: 5
Year
Topic
Type